ADAM17 and cancer: 8 enhances the antitumor effect of cisplatin on ovarian cancer cells through inhibition of ADAM17 and exhibits growth inhibitory effects in a lung adenocarcinoma cell model (Hedemann et al., 2021; Saad et al., 2020) 9 (INCB3619) is a selectively potent and orally bioavailable inhibitor (IC50 = 14 nM), which demonstrated synergy with clinically relevant cancer therapeutics without exhibiting significant or compounding toxicities, including fibroplasia (Fridman et al., 2007).